Skip to main navigation Skip to search Skip to main content

Streamlined resource-efficient plasma amyloid-beta mass spectrometry assay has improved biomarker performance in preclinical Alzheimer’s disease

  • Yijun Chen
  • , Xuemei Zeng
  • , Marcos Olvera-Rojas
  • , Kelsey R. Sewell
  • , Anuradha Sehrawat
  • , Jeremy Gu
  • , Eva María Triviño-Ibañez
  • , Patricio Solis-Urra
  • , Manuel Gómez- Río
  • , Lauren E. Oberlin
  • , Arthur F. Kramer
  • , Charles H. Hillman
  • , Jeffrey M. Burns
  • , Anna L. Marsland
  • , Chaeryon Kang
  • , Edward McAuley
  • , Milos D. Ikonomovic
  • , Tharick A. Pascoal
  • , Victor L. Villemagne
  • , Oscar L. Lopez
  • Ann D. Cohen, Irene Esteban-Cornejo, Nathan A. Yates, Kirk I. Erickson, Thomas K. Karikari

Research output: Contribution to journal › Article › peer-review

Abstract

Plasma amyloid-β (Aβ) peptides, alone or in ratio with p-tau217, show strong potential as Alzheimer’s disease biomarkers. While immunoprecipitation-mass spectrometry (IP-MS) is the preferred method for plasma Aβ quantification, current assays are resource- and time-intensive. Here, we developed a streamlined IP-MS method using a cost-effective instrument that significantly improved the efficiency of an original assay by incorporating a single immunoprecipitation step, an optimized buffer system, and approximately 75% reductions in antibody and sample volume requirements. Technical validation revealed excellent dilution linearity (r²>0.99), high precision (< 10% variation), enhanced sensitivity, improved Aβ recovery, and markedly increased signal-to-noise ratios. In a large cohort of cognitively normal older adults (n = 317), the plasma Aβ1-42/Aβ1-40 ratio achieved stronger concordance with Aβ-PET and superior accuracies to identify abnormal scans (AUC 0.81 vs. 0.65 for the original assay). Notably, accuracies remained high even with plasma volumes as low as 100 μL. The improved IP-MS method enables robust and simplified plasma Aβ assessment in Alzheimer’s disease, with implications for prognosis, diagnosis and intervention trials.

Original languageEnglish (US)
Article number1673
JournalNature communications
Volume17
Issue number1
Early online dateJan 22 2026
DOIs
StatePublished - 2026

ASJC Scopus subject areas

  • General Chemistry
  • General Biochemistry, Genetics and Molecular Biology
  • General
  • General Physics and Astronomy

Fingerprint

Dive into the research topics of 'Streamlined resource-efficient plasma amyloid-beta mass spectrometry assay has improved biomarker performance in preclinical Alzheimer’s disease'. Together they form a unique fingerprint.

Cite this